Collaboration

Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes

June 19, 2018

NEW YORK, June 19, 2018 /PRNewswire/ — Kallyope Inc. and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of […]

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents

June 19, 2018

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts […]

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

June 19, 2018

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) — Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial evaluating Fortress’ CNDO-109-activated allogeneic natural killer (NK) cells in acute myeloid leukemia (AML) patients have been published in the […]

Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.

June 19, 2018

Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter of intent (“LOI”) with Noramco, Inc., pursuant to which the parties have entered into a ninety-day period during which they will negotiate a […]

Parkinson’s Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites That May Contribute to Parkinson’s Disease

June 18, 2018

SUNNYVALE, Calif. & BOSTON & PASADENA, Calif.–(BUSINESS WIRE)–Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced today a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause Parkinson’s Disease (PD). The interventions, to be developed and identified by Axial, will build on the work of Axial’s scientific Co-founder and Caltech Professor, Sarkis […]

Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

June 14, 2018

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and […]

Certara Supports the Not-for-profit Biotechnology Company Medicines Development for Global Health (MDGH) on the FDA New Drug Approval of Moxidectin for the Treatment of River Blindness (Onchocerciasis), a Neglected Tropical Disease

June 14, 2018

Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today celebrated an important milestone for its public health drug development and treatment consulting portfolio. […]

AbCellera Announces Collaboration with Denali Therapeutics to Discover New Antibodies to Treat Neurodegenerative Diseases

June 12, 2018

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera Biologics Inc. today announced the successful completion of the first phase of its collaboration with Denali Therapeutics Inc. (NASDAQ: DNLI). Under the collaboration, AbCellera applied its single-cell screening technology to discover hundreds of novel monoclonal antibodies with specific binding properties against a genetically-validated target for neurodegenerative disease. “The speed and success […]

WuXi AppTec and Insilico Medicine Link Next-Generation Artificial Intelligence and Drug Discovery

June 12, 2018

BALTIMORE, Maryland and SHANGHAI, June 12, 2018 /PRNewswire/ — Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announced that it has entered into a collaboration agreement with WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology […]

Boston U. Boosts Lung Cancer Research with Johnson & Johnson

June 7, 2018

BOSTON (AP) — Boston University is pairing with Johnson & Johnson to help fight lung cancer. School officials announced Wednesday the company will pay for a new lung center at the university where researchers will work to prevent and cure the disease.   It’s part of a five-year research partnership between the school and Johnson […]

Microbiotica Enters into Microbiome Collaboration with Genentech

June 7, 2018

CAMBRIDGE, England–(BUSINESS WIRE)–Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).   Under the terms of the […]

Athersys Announces Expansion of Collaboration With Healios

June 7, 2018

CLEVELAND, Ohio, June 07, 2018 (GLOBE NEWSWIRE) — Athersys, Inc. (NASDAQ:ATHX) announced today that it has entered into an agreement with HEALIOS K.K. (“Healios”) to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment […]

Brainsway and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder

June 7, 2018

HACKENSACK, N.J., June 07, 2018 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, and Cohen Veterans Bioscience, Inc. (CVB), a leading non-profit foundation dedicated to advancing brain disease diagnostic and treatment options for veterans and civilians, today announces the launch of a new research collaboration with the […]

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

June 6, 2018

These in vitro models can help to identify herbal ingredients with the potential to alter the safety or efficacy of prescription drugs   BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am […]

TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer

June 6, 2018

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®), the MEK inhibitor cobimetinib (COTELLIC®) and TESARO’s PARP inhibitor ZEJULA® (niraparib) in patients with platinum-sensitive ovarian cancer. “This partnership enables […]

Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

June 6, 2018

…………………………………………   June 6, 2018 – release at 7:30 am CET Sophia Antipolis, France     Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced its entry into a research collaboration with Ironwood Pharmaceuticals, Inc. (“Ironwood’), a commercial biotechnology company, focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s […]

LakePharma and Harbour Antibodies Announce Partnership for H2L2 Transgenic Mouse Platform for Therapeutic Antibody Discovery

June 6, 2018

BELMONT, Calif. and CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, June 5, 2018 /PRNewswire/ — LakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies’ patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies. […]

Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases

June 6, 2018

CARLSBAD, Calif., June 5, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it closed its expanded strategic collaboration with Biogen (Nasdaq: BIIB) to discover and develop novel antisense drugs for a broad range of neurological diseases following receipt of clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. Biogen paid Ionis […]

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

June 5, 2018

VIENNA & FOSTER CITY, Calif.–(BUSINESS WIRE)–Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, today announced that they have entered into […]

Digital Therapeutics Alliance and USP Announce Collaboration

June 5, 2018

WASHINGTON, June 4, 2018 /PRNewswire-USNewswire/ — The Digital Therapeutics Alliance (DTA) and USP announced a collaboration to explore the development of appropriate standards and guidelines for digital therapeutics at a roundtable discussion co-hosted by the two organizations on May 31, 2018, at USP headquarters in Rockville, MD.   “Innovative digital therapies have the potential to […]

TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer

June 5, 2018

WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®), the MEK inhibitor cobimetinib (COTELLIC®) and TESARO’s PARP inhibitor ZEJULA® (niraparib) in […]

Major Step Forward in Chickpea and Pigeonpea Research – Reference Genome Data Assembled by NRGene & the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT)

June 4, 2018

Ness Ziona, Israel | Hyderabad, Telangana│ Breeding high nutritional varieties of chickpea and pigeonpea just got easier. With new technology, genomic processes that could have taken years have been completed in just a few months. This has been possible by work of scientists from the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) headquartered […]

Bayer Partners with U.S. Department of Energy to Produce Key Starting Material for Xofigo® (radium Ra 223 dichloride) Injection

June 1, 2018

WHIPPANY, N.J., May 31, 2018 /PRNewswire/ — Bayer is collaborating with the U.S. Department of Energy’s Oak Ridge National Laboratory, based in Oak Ridge, TN, to produce actinium-227 (227Ac), the key radioisotope used in the production of the company’s prostate cancer treatment Xofigo® (radium Ra 223 dichloride). The agreement is part of a long term […]

Nosopharm renews its partnership with Inra

May 31, 2018

This second screening campaign aims to discover new classes of antimicrobial agents for treating multi-resistant infections Lyon, France, May 30, 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, today announces that it has renewed its partnership with the French National Institute of Agricultural Research (Inra). This partnership with […]

Aptar Pharma and Propeller Health Partner to Develop Digital Medicine Platform Across Therapeutic Areas

May 30, 2018

CRYSTAL LAKE, Ill. & MADISON, Wis.–(BUSINESS WIRE)–Aptar Pharma, a leading provider of innovative drug delivery systems, and Propeller Health, a leading digital therapeutics company, announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases.   The digital medicine platform, spanning inhaled, injectable, nasal and […]

Schrödinger Announces Oncology Collaboration with Canada’s National Centre for Drug Research and Development to Develop Novel Biologics

May 30, 2018

NEW YORK & VANCOUVER, British Columbia–(BUSINESS WIRE)–Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, announced today that it has established a collaboration with Canada’s national Centre for Drug Research and Development (CDRD), to develop novel immuno-oncology monoclonal antibodies and other cancer biologics. CDRD will provide a portfolio of targeted […]

CENTOGENE Announces Agreement with Aldeyra Therapeutics for the Advancement of Novel Therapeutics for Patients with Sjögren-Larsson Syndrome

May 29, 2018

ROSTOCK, GERMANY, May 29, 2018 – CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced that it has entered into an agreement with Aldeyra Therapeutics Inc., a biotechnology company developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Under the terms of the agreement, […]

CERENIS Therapeutics and University of North Texas Health Science Center announce a strategic initiative to develop new HDL-based pharmaceutical products

May 29, 2018

Toulouse, FRANCE, Fort Worth, UNITED STATES, May 29, 2018, 7.30 am CEST – CERENIS Therapeutics (FR0012616852 – CEREN – PEA-PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of […]

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

May 25, 2018

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.   “Our collaboration with Bicycle continues to be highly productive. By expanding […]

FEEDBACK